October 29, 2019

Whom It May Concern
Company:
Representative:KYORIN Holdings, Inc.
Yutaka Ogihara
Representative Director, President(Security Code: 4569, TSE 1st Sec.)Contact:

Telephone:

Yoshinori Tanifuji
Director, Management Strategy &Planning Division Corporate Planning03-3525-4707

Release of Microchannel-based Genetic Measurement Device GeneSoC®
KYORIN Pharmaceutical Co., Ltd. (head office: Chiyoda-ku, Tokyo; President and CEO:
Shigeru Ogihara;“KYORIN Pharmaceutical”), which is a subsidiary of KYORIN Holdings, Inc.,
will release a microchannel-based genetic measurement device GeneSoC® (“GeneSoc®”) and aspecial-purpose measurement chip based on a basic sales agreement concluded with AS ONE
Corporation (head office: Nishi-ku, Osaka; President and CEO: Takuji Iuchi; “AS ONE”).
Under the Agreement, KYORIN Pharmaceutical will conduct promotional activities jointlywith AS ONE, and AS ONE will sell GeneSoC® as laboratory equipment through its
nationwide distribution network.
These products are scheduled to be released on November 11, and a measuring reagent
specifically designed for GeneSoC® will also be launched subsequently.
GeneSoC® is a compact, super-fast genetic measuring device. It applies microchannel-based
thermal cycle technology*1 developed by the National Institute of Advanced Industrial Scienceand Technology (“AIST”) and was developed jointly by KYORIN Pharmaceutical and AIST.
GeneSoC® can identify a target gene in a sample in a short space of time (around 5-15minutes). As a compact, super-fast genetic measuring device that can identify genes of humans,animals, plants, microorganisms and drug resistance genes in microorganisms quickly, accurately
and simply, this device is expected to be applied in basic and clinical research and in testing forand diagnosing infections and other conditions.
Through the diagnostics using GeneSoC®, KYORIN Pharmaceutical aims to further
contribute to infection control by establishing a business model for the prevention, diagnosis
and treatment of infectious diseases and constantly providing relevant up-to-date
information.
GeneSoC® Product Outline
・Rapid gene detection (around 5-15 minutes) based on super-fast quantitative PCR technology*2
・Desktop PCR device which has been made more compact in anticipation of POCT*3

*1 Microchannel-based thermal cycle technology: Technique for performing PCR by repeatedly moving the measurement sample backward
and forward in a microchannel (specially designed measurement chip) heated by contact with multiple heaters. KYORIN Pharmaceutical has been
granted an exclusive license to use this technology by AIST
*2 P CR (P olym era s e Ch ain R eacti on ): Polymerase Chain Reaction or PCR is a technique used amplify a gene.
*3 POCT (Point of Care Testing): Testing carried out by healthcare professionals at the patient’s bedside

The impact of the release of this product on KYORIN Holdings’ consolidated operating
results for the fiscal year ending March 31, 2020 is minor.
For Reference◆ About AS ONE Corporation
Established in: 1962
President: Takuji Iuchi
Revenue: JPY66,733.18 million (fiscal year ended March 21, 2019)
Number of employees: 557（as of March 31, 2019）
Description of business: Sale of research instruments / equipment, nursing / care products,

other scientific instruments

Overview: Established as Iuchi Seieido Store in 1933, the business changed its company name toAS ONE Corporation upon listing on the first section of the Tokyo Stock Exchange in 2001.
AS ONE Corporation is a general trading firm for scientific equipment. It has a uniquebusiness model, selling almost 4 million items for research, industry and medical fields via
distributors through the use of catalogues and the Internet. AS ONE Corporation contributes
to the development of science and technology by playing a crucial role in the distribution of awide range of specialist products, services and information sought after by researchers and byproviding added value.